ClinicalTrials.gg
Active, not recruitingNCT07303179Updated Feb 10, 2026

Exercise Rehabilitation for Functional Impairment in Maintenance Hemodialysis Patients

An interventional study of Exercise Rehabilitation Therapy (ERT) in End-Stage Renal Disease (ESRD) and Maintenance Hemodialysis (MHD), sponsored by The First People's Hospital of Yunnan. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by The First People's Hospital of Yunnan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2025, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Kidney Failure, Chronic with a site in China — 28 open to participants now, 36 under way, 1 of them phase 3. Kidney Failure, Chronic · China.

Enrollment
57th of 83
60 · median 150
Started
2025
with 11 others
No phase
40 of 114
9 open now
Primary completion
2027-06
later than 24 of 35 live
Registered
101st of 114
by date

Among the 114 studies in Kidney Failure, Chronic with a site in China, this one is the 57th largest by enrollment of the 83 interventional ones that give a count, is one of 12 that started in 2025, is one of 40 with no phase, reaches primary completion later than 24 of the 35 other live ones, and was the 101st registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 114 studies in Kidney Failure, Chronic with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Kidney Failure, Chronic with a site in China, or all of them as a file.
02

Study summary

Maintenance hemodialysis (MHD) is the main treatment for patients with end-stage renal disease (ESRD). Although dialysis prolongs survival, many patients experience reduced physical function, poor quality of life, and higher risks of hospitalization and death. Lack of exercise often leads to muscle weakness and disability, further burdening patients, families, and healthcare systems.

Rehabilitation medicine has shown promise in improving outcomes in patients with chronic kidney disease. Chinese experts have developed the "Standards for Rehabilitation Services in CKD Patients," which outline goals, procedures, and safety measures for exercise interventions. Based on these Standards, this study will evaluate the effects of structured exercise rehabilitation techniques (ERT) during routine dialysis.

This multicenter, randomized controlled trial will enroll 800 patients from 15 dialysis centers in China, including 40 patients at The First People's Hospital of Yunnan Province. Eligible patients will be randomly assigned to an intervention group (dialysis plus ERT) or a control group (dialysis only). ERT includes warm-up, core resistance and cycling exercises, and relaxation, performed 3 times per week for 20-60 minutes per session over 2 years.

The study will assess whether ERT can improve muscle strength, walking distance, psychological health, nutritional and cognitive status, and overall quality of life. Hospitalization and mortality will also be recorded as clinical outcomes. Results will provide scientific evidence for the feasibility, safety, and effectiveness of promoting standardized exercise rehabilitation in MHD patients.

03

Conditions studied

  • End-Stage Renal Disease (ESRD)
  • Maintenance Hemodialysis (MHD)

Keywords

  • Exercise Rehabilitation
  • Maintenance Hemodialysis
  • Physical Function
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. On maintenance hemodialysis for ≥3 months.
  2. Age 18-74 years.
  3. Receiving adequate standard medical management.
  4. Hemodialysis frequency: 3 times per week.
  5. Kt/V > 1.2.

Exclusion criteria

Exclusion Criteria:

  1. (NYHA) class IV heart failure.
  2. Recent uncontrolled unstable angina.
  3. Severe peripheral arterial disease or musculoskeletal disorders.
  4. Walking distance \<200 meters.
  5. Resting oxygen saturation \<90%.
  6. Amputation or other conditions precluding exercise.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Exercise Rehabilitation Group

    This arm will follow the "Standards for Rehabilitation Services in CKD Patients" and receive structured exercise rehabilitation therapy (ERT) in addition to routine hemodialysis. The intervention includes three phases: Warm-up exercises (e.g., stretching, limb flexion/extension, leg raises), Core exercises (e.g., upper-limb resistance training, bedside cycling), Relaxation exercises (e.g., whole-body stretching). Each session will last 20-60 minutes, three times per week, for a total duration of two years. All sessions will be supervised by trained healthcare staff, and exercise prescriptions will be individualized according to patient condition to ensure safety and feasibility.

    Behavioral: Exercise Rehabilitation Therapy (ERT)

  • No intervention
    Control Group

    Participants in this group will receive routine maintenance hemodialysis only, without any additional exercise intervention.

Interventions

  • BehavioralExercise Rehabilitation Therapy (ERT)

    The intervention follows the "Standards for Rehabilitation Services in CKD Patients" and applies structured exercise rehabilitation therapy (ERT) in addition to routine maintenance hemodialysis. The ERT program includes three phases: Warm-up exercises (e.g., stretching, limb flexion/extension, leg raises), Core exercises (e.g., upper-limb resistance training, bedside cycling), Relaxation exercises (e.g., whole-body stretching). Each session will last 20-60 minutes, three times per week, for a total of two years.

    Also known as: Exercise Rehabilitation Therapy, Exercise Training Program

06

What researchers measure

Primary outcomes

  1. Change in 6-minute walk distance (6MWD)

    Functional capacity will be assessed using the 6-minute walk test (6MWT) at baseline and every 6 months. The change in walking distance reflects improvement in functional impairment and exercise tolerance among maintenance hemodialysis (MHD) patients receiving standardized exercise rehabilitation therapy (ERT). Unit of Measure: Meters (m).

    Time frame: From enrollment until 2 years after the end of intervention.

  2. Incidence of hospitalization due to cardiovascular events

    Hospitalizations caused by cardiovascular events will be recorded, including acute myocardial infarction, other acute coronary syndromes, congestive heart failure requiring hospitalization, and severe arrhythmias (e.g., complete atrioventricular block, cardiac arrest). Data will be used to assess whether ERT reduces cardiovascular morbidity. Incidence will be expressed as the proportion of participants experiencing at least one event during the follow-up period.

    Time frame: From enrollment until 2 years after the end of intervention.

  3. Incidence of cerebrovascular events

    The occurrence of cerebrovascular events, including intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke (cardioembolic or other etiologies), will be documented and compared between the ERT and control groups. Incidence will be expressed as the proportion of participants experiencing at least one event during the follow-up period.

    Time frame: From enrollment until 2 years after the end of intervention.

  4. All-cause mortality

    All-cause mortality will be monitored throughout the study to evaluate the long-term safety and prognostic impact of standardized exercise rehabilitation therapy in MHD patients. All-cause mortality will be expressed as the proportion of participants who die from any cause during the follow-up period.

    Time frame: From enrollment until 2 years after the end of intervention.

Secondary outcomes

  1. Change in handgrip strength

    Handgrip strength will be assessed using a calibrated handgrip dynamometer. Measurements will be performed at baseline and every 6 months during the study period. The change in handgrip strength will reflect improvements in upper limb muscle strength among maintenance hemodialysis (MHD) patients receiving standardized exercise rehabilitation therapy (ERT). Unit of Measure: Kilograms (kg)

    Time frame: From enrollment until 2 years after the end of intervention.

  2. Change in lower limb muscle strength assessed by Five Times Sit-to-Stand Test (5STS)

    Lower limb muscle strength will be assessed using the Five Times Sit-to-Stand Test (5STS). Participants will be seated on a standard armless chair (43 cm in height) with feet flat on the floor, arms crossed over the chest, and the back not supported by the chair. Upon the verbal command "start," participants will be instructed to stand up fully and sit down five times as quickly as possible. Timing will begin at the start command and stop when the participant completes the fifth stand. The time required to complete five repetitions will be recorded. Assessments will be performed at baseline and every 6 months during the study period. Changes in 5STS performance will reflect improvements in lower limb muscle function among maintenance hemodialysis patients receiving standardized exercise rehabilitation therapy (ERT). Unit of Measure: Seconds (s)

    Time frame: From enrollment until 2 years after the end of intervention.

  3. Change in depressive symptoms assessed by the Self-Rating Depression Scale (SDS)

    Depressive symptoms will be evaluated using the Self-Rating Depression Scale (SDS), a validated self-report instrument comprising 20 items rated on a 4-point Likert scale. The total raw score is converted to a standard score, with higher scores indicating more severe depressive symptoms. Assessments will be performed at baseline and every 6 months. Changes in SDS scores will reflect the impact of exercise rehabilitation therapy (ERT) on depression among maintenance hemodialysis (MHD) patients. Unit of Measure: Score on a scale (SDS standard score range: 25-100).

    Time frame: From enrollment until 2 years after the end of intervention.

  4. Change in anxiety level assessed by the Self-Rating Anxiety Scale (SAS)

    Anxiety symptoms will be assessed using the Self-Rating Anxiety Scale (SAS), a validated self-administered questionnaire consisting of 20 items. Each item is rated on a 4-point Likert scale. The total raw score is converted to a standard score, with higher scores indicating more severe anxiety symptoms. Assessments will be conducted at baseline and every 6 months during the study period. Changes in SAS scores will be used to evaluate the effect of exercise rehabilitation therapy (ERT) on anxiety levels in maintenance hemodialysis (MHD) patients. Unit of Measure: Score on a scale (SAS standard score range: 25-100).

    Time frame: From enrollment until 2 years after the end of intervention.

  5. Change in body mass index (BMI)

    Body mass index (BMI) will be calculated as body weight divided by the square of height (kg/m²). Measurements will be obtained at baseline and every 6 months. Changes in BMI will be used to evaluate the impact of exercise rehabilitation therapy (ERT) on body composition and nutritional status in maintenance hemodialysis (MHD) patients. Unit of Measure: Kilograms per square meter (kg/m²).

    Time frame: From enrollment until 2 years after the end of intervention.

  6. Change in cognitive function assessed by the Montreal Cognitive Assessment (MoCA)

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA) at baseline and every 6 months. The MoCA is a 30-point cognitive screening tool evaluating domains including attention, memory, language, and executive function, where higher scores indicate better cognitive performance. Changes in MoCA scores will be used to assess the effect of exercise rehabilitation therapy (ERT) on cognitive function in maintenance hemodialysis (MHD) patients. Unit of Measure: Score on a scale (MoCA score range: 0-30).

    Time frame: From enrollment until 2 years after the end of intervention.

  7. Change in self-management ability assessed by the Hemodialysis Self-Management Scale

    Self-management ability will be assessed using the Hemodialysis Self-Management Scale, a 20-item patient-reported questionnaire designed to evaluate self-management behaviors in patients undergoing maintenance hemodialysis. The scale assesses domains such as treatment adherence, dietary and fluid management, symptom monitoring, and health-related behaviors. Assessments will be conducted at baseline and every 6 months during the study period. Changes in self-management scores will be used to evaluate the effect of exercise rehabilitation therapy (ERT) on self-management ability in maintenance hemodialysis (MHD) patients. Unit of Measure: Score on a scale (total score; range: 0-20)

    Time frame: From enrollment until 2 years after the end of intervention.

  8. Change in urea reduction ratio (URR)

    Urea reduction ratio (URR) will be calculated based on pre- and post-dialysis blood urea levels at baseline and every 3 months to evaluate dialysis adequacy. Unit of Measure: Percent (%). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  9. Change in single-pool Kt/V for urea

    Single-pool Kt/V for urea will be calculated at baseline and every 3 months using pre- and post-dialysis blood urea concentrations to assess dialysis adequacy in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Dimensionless. Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  10. Change in hemoglobin concentration

    Hemoglobin concentration will be measured at baseline and every 3 months to evaluate changes in anemia status in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Grams per liter (g/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  11. Change in serum ferritin

    Serum ferritin levels will be measured at baseline and every 3 months to assess changes in iron stores in MHD patients undergoing exercise rehabilitation therapy (ERT). Unit of Measure: Nanograms per milliliter (ng/mL). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  12. Change in transferrin saturation (TSAT)

    Transferrin saturation (TSAT) will be calculated at baseline and every 3 months to evaluate iron utilization in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Percent (%). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  13. Change in serum calcium

    Serum calcium levels will be measured at baseline and every 3 months to assess changes in mineral metabolism in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Millimoles per liter (mmol/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  14. Change in serum phosphate

    Serum phosphate concentrations will be measured at baseline and every 3 months to evaluate changes in mineral metabolism in maintenance hemodialysis (MHD) patients undergoing exercise rehabilitation therapy (ERT). Unit of Measure: Millimoles per liter (mmol/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  15. Change in intact parathyroid hormone (iPTH)

    Serum intact parathyroid hormone (iPTH) levels will be measured at baseline and every 3 months to assess changes in parathyroid function and mineral bone disorder status in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Picograms per milliliter (pg/mL). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  16. Change in C-reactive protein (CRP)

    Serum C-reactive protein (CRP) levels will be measured at baseline and every 3 months to assess changes in systemic inflammation associated with exercise rehabilitation therapy (ERT) in maintenance hemodialysis (MHD) patients. Unit of Measure: Milligrams per liter (mg/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  17. Change in serum albumin

    Serum albumin concentration will be measured at baseline and every 3 months to evaluate changes in nutritional status in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Grams per liter (g/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  18. Change in prealbumin

    Serum prealbumin levels will be assessed at baseline and every 3 months to evaluate short-term changes in nutritional status in maintenance hemodialysis (MHD) patients undergoing exercise rehabilitation therapy (ERT). Unit of Measure: Milligrams per liter (mg/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  19. Change in triglycerides

    Serum triglyceride levels will be measured at baseline and every 3 months to assess changes in lipid metabolism in maintenance hemodialysis (MHD) patients receiving exercise rehabilitation therapy (ERT). Unit of Measure: Millimoles per liter (mmol/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

  20. Change in total cholesterol

    Total serum cholesterol levels will be measured at baseline and every 3 months to evaluate changes in lipid profile in maintenance hemodialysis (MHD) patients undergoing exercise rehabilitation therapy (ERT). Unit of Measure: Millimoles per liter (mmol/L). Laboratory parameters are assessed every 3 months in accordance with routine clinical monitoring practices in maintenance hemodialysis patients.

    Time frame: From enrollment until 2 years after the end of intervention.

Other outcomes

  1. Correlation between metabolomic and proteomic features and 6-minute walk distance (6MWD)

    Untargeted metabolomic and proteomic profiling will be performed on blood samples collected at baseline and follow-up using liquid chromatography-mass spectrometry (LC-MS/MS). Normalized relative abundances of detected metabolites and proteins will be correlated with 6-minute walk distance (6MWD) measured by the 6-minute walk test. Correlation analyses will be conducted to identify molecular features associated with functional capacity and responsiveness to exercise rehabilitation therapy (ERT) in maintenance hemodialysis (MHD) patients. Unit of Measure: Correlation coefficient (Pearson or Spearman correlation will be used depending on data distribution).

    Time frame: From baseline sampling to 2 years after the end of intervention.

  2. Correlation between metabolomic and proteomic features and depressive symptoms (Self-Rating Depression Scale, SDS)

    Untargeted metabolomic and proteomic profiling will be performed on blood samples collected at baseline and follow-up using LC-MS/MS. Normalized relative abundances of detected metabolites and proteins will be correlated with depressive symptom severity assessed by the Self-Rating Depression Scale (SDS). The SDS standard score ranges from 25 to 100, where higher scores indicate more severe depressive symptoms. Correlation analyses will be performed to identify molecular features associated with depressive symptoms and psychological responsiveness to ERT in MHD patients. Unit of Measure: Correlation coefficient (Pearson or Spearman correlation will be used depending on data distribution.).

    Time frame: From baseline sampling to 2 years after the end of intervention.

  3. Correlation between metabolomic and proteomic features and cognitive function (Montreal Cognitive Assessment, MoCA)

    Untargeted metabolomic and proteomic profiling will be performed using LC-MS/MS. Normalized molecular feature abundances will be correlated with cognitive function assessed by the Montreal Cognitive Assessment (MoCA), a 30-point cognitive screening tool, where higher scores indicate better cognitive performance. Unit of Measure: Correlation coefficient (Pearson or Spearman correlation will be used depending on data distribution).

    Time frame: From baseline sampling to 2 years after the end of intervention.

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 24 months is close to that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Dec 24, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 30, 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07303179
Lead sponsor
The First People's Hospital of Yunnan
Responsible party
Qinyuan Deng (Resident Physician, The First People's Hospital of Yunnan) — Principal investigator
First posted
Dec 24, 2025
Start date
Jun 1, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion